Breast cancer drug that doubles survival time is available on NHS after watchdog U-turns

Breast cancer drug that doubles survival time is available on NHS after watchdog U-turns A breast cancer drug that almost doubles a patient’s survival time will now be available on the NHS in England after a U-turn from the watchdog.

The National Institute for Health and Care Excellence (Nice) rejected sacituzumab govitecan, also known as Trodelvy, for use in England in April after saying it was “too expensive” to be cost effective. The Daily Telegraph

See also:

• NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018 National Institute for Health and Care Excellence
• Two breast cancer drugs available on NHS in England after U-turn The Guardian